Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Paul M Beringer, PharmD

    TitleAssociate Professor of Clinical
    SchoolSchool of Pharmacy
    DepartmentClinical Pharmacy and Pharmaceutical Econ. and Policy
    AddressPSC B15
    Health Sciences Campus
    Los Angeles California 90089-9121
    Phone+1 323 442 1402
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Dr. Beringer’s research focus is on cystic fibrosis, a genetic disorder which results in defective chloride transport within the apical membrane of epithelial cells throughout the body. The principal cause of morbidity and mortality arises from chronic pulmonary infections resulting in bronchiectasis and progressive loss of lung function and eventual respiratory failure. Dr. Beringer’s group is interested in optimizing the use of pharmacologic therapies to preserve lung function and quality of life for individuals afflicted with CF.

      Ongoing research projects include: the study of the mechanistic basis of the enhanced renal clearance of antibiotics in CF; the use of novel clinical measures of glomerular filtration to improve drug dosing; and impact of pancreatic insufficiency on oral bioavailability of antibiotics.

      Biography: Dr. Beringer received his Pharm.D. degree from the USC School of Pharmacy. He completed a pharmacy practice residency and specialty residency in pharmacokinetics at the University of California at San Francisco. Currently, he is an associate professor of clinical pharmacy (USC School of Pharmacy) and associate professor of clinical medicine with the department of pulmonary and critical care medicine (USC Keck School of Medicine).

      Dr. Beringer's clinical expertise is in the area of cystic fibrosis pharmacotherapy. He has authored numerous journal articles and book chapters in the area of pharmacokinetics and cystic fibrosis.


      Collapse Biography 
      Collapse Clinical Trials

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Beringer P, Bensman TJ, Ho H, Agnello M, Denovel N, Nguyen A, Wong-Beringer A, She R, Tran DQ, Moskowitz SM, Selsted ME. Rhesus ?-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa. J Antimicrob Chemother. 2016 Jan; 71(1):181-8. PMID: 26433781.
        View in: PubMed
      2. Ha H, Debnath B, Odde S, Bensman T, Ho H, Beringer P, Neamati N. Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models. J Chem Inf Model. 2015 Aug 24; 55(8):1720-38. PMID: 26153616.
        View in: PubMed
      3. Ha H, Bensman T, Ho H, Beringer P, Neamati N. A novel phenylcyclohex-1-enecarbothioamide derivative inhibits CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signalling. Br J Pharmacol. 2014 Mar; 171(6):1551-65. PMID: 24354854.
        View in: PubMed
      4. Bensman TJ, Nguyen AN, Rao AP, Beringer P. Doxycycline exhibits anti-inflammatory activity in CF bronchial epithelial cells. Pulm Pharmacol Ther. 2012 Oct; 25(5):377-82. PMID: 22771903.
        View in: PubMed
      5. Haas CE, Eckel S, Arif S, Beringer P, Blake EW, Lardieri AB, Lobo BL, Mercer JM, Moye P, Orlando PL, Wargo K. Acute Care Clinical Pharmacy Practice: Unit- versus Service-Based Models. Pharmacotherapy. 2012 Feb; 32(2):e35-44. PMID: 22392430.
        View in: PubMed
      6. Beringer P, Owens H, Nguyen A, Benitez D, Rao A, D'Argenio DZ. Pharmacokinetics of doxycycline in adults with cystic fibrosis. Antimicrob Agents Chemother. 2012 Jan; 56(1):70-4. PMID: 22024822.
        View in: PubMed
      7. Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother. 2011 Jul; 55(7):3278-83. PMID: 21576448.
        View in: PubMed
      8. Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents. 2011 Feb; 37(2):95-101. PMID: 21130609.
        View in: PubMed
      9. Beringer P, Owens H, Nguyen A, Mordwinkin N, Louie S, Mak M, Sattler F. Estimation of glomerular filtration rate by using serum cystatin C and serum creatinine concentrations in patients with human immunodeficiency virus. Pharmacotherapy. 2010 Oct; 30(10):1004-10. PMID: 20874037.
        View in: PubMed
      10. Dowling TC, Murphy JE, Kalus JS, Nkansah NT, Chappell JS, Wiederhold NP, Beringer P, Crews KR, Grabinski JL, Evens RP, Leff R. Recommended education for pharmacists as competitive clinical scientists. Pharmacotherapy. 2009 Feb; 29(2):236-44. PMID: 19170592.
        View in: PubMed
      11. Beringer P, Hidayat L, Heed A, Zheng L, Owens H, Benitez D, Rao AP. GFR estimates using cystatin C are superior to serum creatinine in adult patients with cystic fibrosis. J Cyst Fibros. 2009 Jan; 8(1):19-25. PMID: 18799365.
        View in: PubMed
      12. Beringer P, Kriengkauykiat J, Zhang X, Hidayat L, Liu S, Louie S, Synold T, Burckart GJ, Rao PA, Shapiro B, Gill M. Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis. Pharmacotherapy. 2008 Jul; 28(7):883-94. PMID: 18576903.
        View in: PubMed
      13. Liu S, Beringer P, Hidayat L, Rao AP, Louie S, Burckart GJ, Shapiro B. Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine. J Clin Pharmacol. 2008 Aug; 48(8):957-65. PMID: 18511651.
        View in: PubMed
      14. Han EE, Beringer P, Falck P, Louie S, Rao P, Shapiro B, Gill M. Pilot study of continuous infusion cefepime in adult patients with cystic fibrosis. J Antimicrob Chemother. 2006 May; 57(5):1017-9. PMID: 16533828.
        View in: PubMed
      15. Beringer P, Huynh KM, Kriengkauykiat J, Bi L, Hoem N, Louie S, Han E, Nguyen T, Hsu D, Rao PA, Shapiro B, Gill M. Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. Antimicrob Agents Chemother. 2005 Dec; 49(12):5013-7. PMID: 16304166.
        View in: PubMed
      16. Wong-Beringer A, Lambros MP, Beringer P, Johnson DL. Suitability of caspofungin for aerosol delivery: physicochemical profiling and nebulizer choice. Chest. 2005 Nov; 128(5):3711-6. PMID: 16304338.
        View in: PubMed
      17. Beringer P, Nguyen M, Hoem N, Louie S, Gill M, Gurevitch M, Wong-Beringer A. Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. Antimicrob Agents Chemother. 2005 Sep; 49(9):3676-81. PMID: 16127039.
        View in: PubMed
      18. Beringer P, Slaughter RL. Transporters and their impact on drug disposition. Ann Pharmacother. 2005 Jun; 39(6):1097-108. PMID: 15886292.
        View in: PubMed
      19. Garcia AA, Pujari M, Jeffers S, Iqbal S, Lenz HJ, Beringer P, Louie S. Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule. Cancer Chemother Pharmacol. 2005 Jul; 56(1):75-82. PMID: 15809878.
        View in: PubMed
      20. Swadron SP, Rudis MI, Azimian K, Beringer P, Fort D, Orlinsky M. A comparison of phenytoin-loading techniques in the emergency department. Acad Emerg Med. 2004 Mar; 11(3):244-52. PMID: 15001403.
        View in: PubMed
      21. Han EE, Beringer P, Louie SG, Gill MA, Shapiro BJ. Pharmacokinetics of Ibuprofen in children with cystic fibrosis. Clin Pharmacokinet. 2004; 43(3):145-56. PMID: 14871154.
        View in: PubMed
      22. Sprauten PF, Beringer P, Louie SG, Synold TW, Gill MA. Stability and antibacterial activity of cefepime during continuous infusion. Antimicrob Agents Chemother. 2003 Jun; 47(6):1991-4. PMID: 12760882.
        View in: PubMed
      23. Nguyen T, Louie SG, Beringer P, Gill MA. Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease. Curr Opin Pulm Med. 2002 Nov; 8(6):521-8. PMID: 12394161.
        View in: PubMed
      24. Aminimanizani A, Beringer P, Kang J, Tsang L, Jelliffe RW, Shapiro BJ. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. J Antimicrob Chemother. 2002 Oct; 50(4):553-9. PMID: 12356801.
        View in: PubMed
      25. Beringer P, Aminimanizani A, Synold T, Scott C. Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. Ther Drug Monit. 2002 Apr; 24(2):315-21. PMID: 11897978.
        View in: PubMed
      26. Montgomery MJ, Beringer P, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, Gill MA. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 2001 Dec; 45(12):3468-73. PMID: 11709326.
        View in: PubMed
      27. Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med. 2001 Nov; 7(6):434-40. PMID: 11706322.
        View in: PubMed
      28. Aminimanizani A, Beringer P, Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet. 2001; 40(3):169-87. PMID: 11327197.
        View in: PubMed
      29. Montgomery MJ, Beringer P, Louie SG, Gill MA. Estimation of creatinine clearance in patients with metastatic ovarian cancer. Ther Drug Monit. 2000 Dec; 22(6):695-700. PMID: 11128237.
        View in: PubMed
      30. Beringer P, Appleman MD. Unusual respiratory bacterial flora in cystic fibrosis: microbiologic and clinical features. Curr Opin Pulm Med. 2000 Nov; 6(6):545-50. PMID: 11100967.
        View in: PubMed
      31. Beringer P, Vinks AA, Jelliffe RW, Shapiro BJ. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob Agents Chemother. 2000 Apr; 44(4):809-13. PMID: 10722474.
        View in: PubMed
      32. Beringer P. New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis. Curr Opin Pulm Med. 1999 Nov; 5(6):371-7. PMID: 10570739.
        View in: PubMed
      33. Beringer P, Wong-Beringer A, Rho JP. Predictive performance of a vancomycin-aminoglycoside population model. Ann Pharmacother. 1998 Feb; 32(2):176-81. PMID: 9496400.
        View in: PubMed
      34. Beringer P, Vinks AA, Jelliffe RW. Pharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis. J Antimicrob Chemother. 1998 Jan; 41(1):142-4. PMID: 9511054.
        View in: PubMed
      35. Beringer P, Wong-Beringer A, Rho JP. Economic aspects of antibacterial adverse effects. Pharmacoeconomics. 1998 Jan; 13(1 Pt 1):35-49. PMID: 10175984.
        View in: PubMed
      36. Wong-Beringer A, Beringer P, Lovett MA. Successful treatment of multidrug-resistant Pseudomonas aeruginosa meningitis with high-dose ciprofloxacin. Clin Infect Dis. 1997 Oct; 25(4):936-7. PMID: 9356822.
        View in: PubMed
      37. Beringer P, Rho JP. Is routine measurement of free phenytoin concentrations rational? Ther Drug Monit. 1995 Aug; 17(4):381-2. PMID: 7482694.
        View in: PubMed